Mostrando 7 resultados de: 7
Subtipo de publicación
Article(7)
Publisher
American Heart Journal(2)
New England Journal of Medicine(2)
Circulation(1)
Journal of the American College of Cardiology(1)
The Lancet Diabetes and Endocrinology(1)
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
ArticleAbstract: Background-Clinical trials in heart failure have focused on the improvement in symptoms or decreasesPalabras claves:Angiotensin, Heart Failure, Neprilysin, ReceptorsAutores:Andersen K., Arango J.L., Arnold J.M., Belohlávek J., Böhm M., Boytsov S., Burgess L.J., Cabrera W., Calvo C., Chen C.H., Desai A.S., Dukat A., Erglis A., Fu M., Gomez E., Gong J., Gonzàlez-Medina A., Hagège A.A., Huang J., Katova T., Kiatchoosakun S., Kim K.S., Kozan Ö., Lefkowitz M.P., Llamas E.B., Martinez F., McMurray J.J.V., Mendoza I., Merkely B., Mosterd A., Negrusz-Kawecka M., Packer M., Peuhkurinen K., Ramires F.J.A., Refsgaard J., Rizkala A.R., Rosenthal A., Rouleau J.L., Senni M., Shi V.C., Sibulo A.S., Silva-Cardoso J., Solomon S.D., Squire I.B., Starling R.C., Swedberg K., Teerlink J.R., Vanhaecke J., Vinereanu D., Wong R.C.C., Yan Duarte, Zile M.Fuentes:scopusAlirocumab and cardiovascular outcomes after acute coronary syndrome
ArticleAbstract: BACKGROUND Patients who have had an acute coronary syndrome are at high risk for recurrent ischemicPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Ducrocq G., Eapen Z., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Quintero K., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valdovinos P.C.M., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:scopusEffects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
ArticleAbstract: Background: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovasculPalabras claves:Autores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Colhoun H.M., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., DIaz R., Dilic M., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Loizeau V., Lopes R.D., Mahaffey K.W., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopusLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
ArticleAbstract: Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for mPalabras claves:acute coronary syndrome, lipoprotein(a), low-density lipoprotein cholesterol, PCSK9 inhibitorAutores:Alexander J.H., Alexander K., Alings M., Armaganijan L., Aylward P.E., Bagai A., Bahit M.C., Bhatt D.L., Bittner V.A., Brennan J.M., Budaj A.J., Chaitman B., Chiang C.E., Chua T., Chumburidze V., Clifton S., Correa Flores R.M., Dalby A.J., Danchin N., De Silva H.A., Deloatch S., Devore A.D., DIaz R., Dickey S., Dilic M., Dombrowski K., Dorobantu M., Drexel H., Edelberg J.M., Erglis A., Fras Z., Goodman S.G., Gotcheva N.N., Guneri S., Hagström E., Halvorsen S., Hanotin C., Harrington R.A., Jukema J.W., Karpov Y., Kedev S., Kelsey S.F., Kim H.S., Kim S.H., Kimura T., Kiss R.G., Landmesser U., Laucevicius A., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., Meloni C., Montenegro Valdovinos P.C., Morais J., Moriarty P.M., Moryusef A., Müller C.E., Murin J., Nieminen M.S., Olsson A.G., Ostadal P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Ramos López G.A., Ray K.K., Reiner Z., Ristic A.D., Roe M.T., Rosenson R., Rouleau J.L., Sasiela W.J., Scemama M., Schwartz G.G., Sijbrands E.J.G., Simoons M.L., Sinnaeve P.R., Sritara P., Steg P.G., Sy R.G., Szarek M., Tamby J.F., Tricoci P., Tse H.F., Tuñón J., Valgimigli M., Viigimaa M., Vogel R., White H.D., Xavier D., Yong H., Yusoff K., Zahger D., Zeiher A.M.Fuentes:googlescopusRationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)
ArticleAbstract: Aims Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insPalabras claves:Autores:Accatoli A., AHUAD GUERRERO R.A., Alvarez C., Alvarisqueta A., Amuchastegui M., Angos M., Ankudowikz V., Arias P., Baglivo H., Bagur R., Baigorria A., Baselga P., Bello F., Bertrand B., Birkeland K.I., Bono J., Bosch J.J., Brito S., Budaj A.J., Bustamante Labarta M., Bustos B., Buzeki R., Cabut A.M., CACCAVO A., Cantalupi H., Canteros M.C., Capozzi M.N., Cardona E., Cardone M., CARTASEGNA L.U.I.S., Cassetari A., Castano P., Castellanos R., Cerdan M.A., Chazova I.E., Cismondi M.T., Commerford P.J., Contreras A., Coria G., Corinaldesi F., Costa G., Costa Vitali A., Crespo C., Cruz M., Cuello J.L., Cuneo C.A., Dagenais G.R., Danilova L., Davies M., De Loredo L., De Maria M., Denaro R., Devoto C., Díaz R., Faingold C., Falu R., Fernando R., Fodor G.J., Gamiz J., Gerstein H.C., Gilbert R., Gomis R., Hâncu N., Hanefeld M., Hildebrandt P., Johnston P., Kacerovsky-Bielesz G., Keltai M., Kim J., Krum H., Kultursay H., Lanas F.T., Lewis B.S., Lonn E.M., Maggioni A.P., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mendoza I., Morillo C.A., Pan C., PATRICIO LOPEZ -JARAMILLO, Pirags V., Probstfield J.L., Profozic V., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rouleau J.L., Rydén L.E., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Vige R., Yale J.F., Yusuf S.Fuentes:scopusRationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
ArticleAbstract: Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patientsPalabras claves:Autores:Aguilar D., Aizenberg D., Allen P., Alvarez C., Alvarisqueta A., Amerena J., Baccaro C., Barkoudah E., BARTOLACCI I.P., Bentley-Lewis R., BORDONAVA A.P., Brahimi A., Bustamante Labarta M., CACCAVO A., Calella P., Cantero M., Charytan D., Chaturvedi N., Claggett B., Codutti R., Commendatore V., Costamagna O., Cuello J.L., Danilova L., Del Prato S., DeMets D., DIaz R., Dickstein K., Fasching P., Fernandez A., Finn P., Flynn A., GARCIA DURAN R.O., Gerstein H.C., Gomez Vilamajo O., Gorban De Lapertosa S., Granger C.B., GRINFELD D., Hartley L.H., Henderson G., Hermida S., Johnston P., Joseph J., Kaplan A., Køber L.V., Lagrutta M., Lawson F., Leon De La Fuente R., Lewis E.F., Licheri A., Lieberman P., LUCIARDI H.L., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Marino J., McMurray J.J.V., Montaña O., Novaretto L., O'Reilly E., Odutayo K., Orio S., Orlandini A., Oviedo A., Patel K., Patocchi C., Paul V., Pérez Manghi F., Petrie J., Pfeffer M.A., Pieber T., Ping L., Probstfield J.L., Raccah D., Rajesh V., Ramos H., Riddle M.C., Rolandi F., Rouleau J.L., Saa Zarandon R., Saavedra S.S., Sangla K., Scarpa A., Schattner M., SCHIAVI L.B., SCHYGIEL P.O., Solomon S.D., Tardif J.C., Trivi M., Ulla M., Urdiales P., Vallejos J., Van Gaal W., Vazir A., VICO M., Waisman F., Weinrauch L., Wu Y., Yan C. Duarte-Vera, Yeap B., Zuraw B.L.Fuentes:scopusRivaroxaban with or without aspirin in stable cardiovascular disease
ArticleAbstract: BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effePalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhagirath V., Bhatt D.L., Bogaty P.M., Bosch J.J., Botto F., Branch K.R.H., Bruns N.C., Cairns J., Carlos Ernesto Peñaherrera, Casanova A., Catanese L., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DeMets D., Deng E., DIaz R., Donato Magno J., Edgar B. Rodas, Eikelboom J.W., Ertl G., Fabbri G., Felix Camilo, Fox K.A.A., Gabizon I., Gosselin G., Goto S., Guzik T.J., Ha J., Halon D., Hart R.G., Heldmann M., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamelas P.M., Lamy A., Lanas F., Lauw M., Leong D.P., Leong Y., Lewis B.S., Liang D., Liang Y., Liu L., Lonn E.M., Lutay Y., Maggioni A.P., Maly M., María José Paucar, Metsarinne K.P., Mikulik R., Misselwitz F., Moayyedi P., Momomura S.I., Nayar S., Ng K., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Perera K., Piegas L.S., Pirvu O., Pogosova N., Prins M., Probstfield J.L., Ramsay T., Ronner E., Rouleau J.L., Rydén L.E., Sato S., Schumi J., Sharma M., Shestakovska O., Shirley Guamán, Silvia Cáceres, Sleight P., Smyth A., Sokolova E., Steg P.G., Stoerk S., Störk S., Thabane L., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Wiendl M., Winkelmann B., Yan Duarte, Yang X., Yufereva Y., Yusoff K., Yusuf S., Zhu J.Fuentes:scopus